The biology of CD20 and its potential as a target for mAb therapy
MS Cragg, CA Walshe, AO Ivanov… - B cell trophic factors and B …, 2005 - karger.com
CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …
The biology of CD20 and its potential as a target for mAb therapy
MS Cragg, CA Walshe, AO Ivanov… - Current directions in …, 2005 - pubmed.ncbi.nlm.nih.gov
CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …
The biology of CD20 and its potential as a target for mAb therapy
MS Cragg, CA Walshe, AO Ivanov, MJ Glennie - 2005 - eprints.soton.ac.uk
CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …
The Biology of CD20 and Its Potential as a Target for mAb Therapy
MS Cragg, CA Walshe, AO Ivanov… - B Cell Trophic Factors …, 2005 - books.google.com
Abstract CD20 is a 33–37kDa, non-glycosylated phosphoprotein expressed on the surface
of almost all normal and malignant B cells. It is also the target for rituximab, the most effective …
of almost all normal and malignant B cells. It is also the target for rituximab, the most effective …
The biology of CD20 and its potential as a target for mAb therapy.
MS Cragg, CA Walshe, AO Ivanov… - Current Directions in …, 2005 - europepmc.org
CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …